A BH3 Mimetic for Killing Cancer Cells.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27315468.
- Also identified by DOI 10.1016/j.cell.2016.05.080.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Venetoclax is a BH3 mimetic approved for treating chronic lymphocytic leukemia. Cancer cells are resistant to apoptosis but "primed for death" by elevated BCL-2, which binds to pro-apoptotic proteins and holds them in check. Venetoclax releases this antagonism and is the first approved drug to target a protein-protein interaction.
Medical subject headings
- Antineoplastic Agents
- Bridged Bicyclo Compounds, Heterocyclic
- Drug Approval
- Leukemia, Lymphocytic, Chronic, B-Cell
- Sulfonamides